Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy

Bibliography

• LOWENSTEIN PR, MORRISON EE, BAIN D et al: Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins in postmitotic polarized cortical neurons and glial cells in vitro. Neuroscience (1994) 60:1059–1077.
   PubMed Web of Science ®Google Scholar
• WIELBO D, SERNIA C, GYURKO R, PHILLIPS MI: Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension (1995) 25:314–319.
   PubMed Web of Science ®Google Scholar
• ZLOKOVIC BV, APUZZO MU: Cellular and molecular neurosurgery: pathways from concept to reality -- Part II: Vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery (1997) 40:805–813.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI: Modulation of blood-brain barrier permeability. I Drug Targeting (1996) 3:417–425.
   PubMed Web of Science ®Google Scholar
• SCHINKEL AH, SMIT JJ, VAN TELLINGEN 0 et al: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 77:491–502.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI: Blood-Brain Barrier in Physiology and Medicine. Raven Press, New York, USA (1976).
   Google Scholar
• •A review of structure and function of BBB.
   Google Scholar
• STADDON JM, RUBIN LL: Cell adhesion, cell junctions and the blood-brain barrier. Curr. Opiri. Neurobial (1996) 6:622–627.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI, ROBINSON PJ: Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann. NY Acad. Sci. (1986) 481:250–267.
   PubMed Web of Science ®Google Scholar
• OHNO K, PETTI GREW KD, RAPOPORT SI: Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am. Physial (1978) 235:H299–H307.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI, HORI M, KLATZO I: Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am. I Physial (1972) 223:323–331.
   PubMed Web of Science ®Google Scholar
• ROBINSON PJ, RAPOPORT SI: Size selectivity of blood-brain barrier permeability at various times after osmotic opening. Am. J. Physial. (1987) 253:R459–R466.
   Web of Science ®Google Scholar
• BRIGHTMAN MW HORI M, RAPOPORT SI, REESE TS, WESTERGAARD E: Osmotic opening of tight junctions in cerebral endothelium. Comp. Neural. (1973) 152:317–325.
   PubMed Web of Science ®Google Scholar
• DOROVINI-ZIS K, SATO M, GOPING G, RAPOPORT SI, BRIGHTMAN M: Ionic lanthanum passage across cerebral endothelium exposed to hyperosmotic arabinose. Acta Neurapathol. (Berlin) (1983) 60:49–60.
   PubMed Web of Science ®Google Scholar
• DOROVINI-ZIS K, BOWMAN PD, BETZ AL, GOLDSTEIN GW: Hyperosmotic arabinose solutions open tight junctions between brain capillary endothelial cells in tissue culture. Brain Res. (1984) 302:383–386.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI, THOMPSON HK: Osmotic opening of the blood-brain barrier in the monkey without associated neurological deficits. Science (1973) 180:971.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI, FREDERICKS WR, OHNO K, PETTI GREW KD: Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am. j Physial. (1980) 238:R421–R431.
   Web of Science ®Google Scholar
• ••Most complete description of quantitativeaspects of osmotic barrier opening in rats.
   Google Scholar
• NEU WELT EA, FRENKEL EP, DIEHL J, VU LH, RAPOPORT SI, HILL SA: Reversible osmotic blood-brain barrier disruption in humans: Implication for the chemotherapy of malignant brain tumors. Neurosurgery (1980) 7:44–52.
   PubMed Web of Science ®Google Scholar
• TOMIWA K, HAZAMA E MIKAWA H: Reversible osmotic opening of the blood-brain barrier: prevention of tissue damage with filtration of the perfusate. Acta Pathal fpri. (1982) 32:427–435.
   PubMedGoogle Scholar
• NEUWELT EA, GLASBERG M, FRENKEL E, BARNETT P: Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann. Neural. (1983) 14:316–324.
   PubMed Web of Science ®Google Scholar
• COSOLO WC, MARTINELLO P, LOUIS WJ, CHRISTOPHIDIS N: Blood-brain barrier disruption using mannitol: time course and electron microscopic studies. Am. Physial. (1989) 256: R443–R447.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI: Microinfarction: osmotic BBB opening of microcrystals in infusate? Neurosurg. (1991) 74:685.
   Google Scholar
• REMSEN LG, PAGEL M, MCCORMICK DI, FLAMENGO SA, SEXTON G, NEU WELT EA: The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts. Ariesth. Arialg. (1999) 88:559–567.
   PubMed Web of Science ®Google Scholar
• SUZUKI M, IWASAKI Y, YAMAMOTO T, KONNO H, KUDO H: Sequelae of the osmotic blood-brain barrier opening in rats. Neurosurg. (1988) 69:421–428.
   Web of Science ®Google Scholar
• SALAHUDDIN TS, JOHANSSON BB, KALIMO H, OLSSON Y: Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study Acta Neuropathol. (Berl.) (1988) 77:5–13.
   PubMed Web of Science ®Google Scholar
• GUMERLOCK MK, NEU WELT EA: Theeffects of anesthesia on osmotic blood-brain barrier disruption. Neurosurgery (1990) 26:268–277.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI: Mathematical model forbrain edema. j Theoret. Biol. (1978) 74:439–467.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI: A model for brain edema. In: Brain Edema, Proceedings of the Sixth International Symposium.Y Inaba, I Klatzo, M Spatz (Eds). Berlin, Springer Verlag, Germany (1985):59–71.
   Google Scholar
• ROSOMOFF HL: Distribution of intracranial contents after hypertonic urea. Neurosurg. (1962) 19:859–864.
   Web of Science ®Google Scholar
• RAPOPORT SI: Osmotic opening of the blood-brain barrier: Principles, mechanism and therapeutic applications. Cell Ma Neurobiol. (2000) 20:217–230.
   PubMed Web of Science ®Google Scholar
• WONG AJ, GOTTLEIB Al: Endothelial cell monolayer integrity. I. Characterization of dense peripheral band of microfilaments. Arteriosclerosis (1986) 6:212–219.
   Google Scholar
• OLESEN SP: Regulation of ion permeability in frog brain venules. Significance of calcium, cyclic nucleotides and protein kinase C. I Physiol. (Lond.) (1987) 387:59–69.
   Google Scholar
• ABBOTT NJ, REVEST PA: Control of brain endothelial permeability. Cerebrovasc. Broth Metab. Rev (1991) 3:39–72.
   PubMedGoogle Scholar
• NAGASHIMA T, SHIJING W, MIZOGUCHI A, TAMAKI N: A possible role of calcium ion in osmotic opening of blood-brain barrier. I Auton Nerv. System (1994) 49(Suppl.): S145–S149.
   Google Scholar
• NAGASHIMA T, IDEDA K, WU S, KONDO T, YAMAGUCHI M, TAMAKI N: The mechanism of reversible opening of the blood-brain barrier: Role of intracellular calcium ion in capillary endothelial cells. Acta Neurochir (1997) 70(Suppl.):231–233.
   Google Scholar
• OIKE M, DROOGMANS G, NILIUS B: Mechanosensitive Ca2+ transients in endothelial cells from human umbilical vein. Proc. Natl. Acad. Sci. USA (1994) 91:2940–2944.
   PubMed Web of Science ®Google Scholar
• JENA M, MINORE JF, O'NEILL WC: A volume-sensitive, 1P3-insensitive Ca2+ store in vascular endothelial cells. Am. I Physiol. (1997) 273:C316–C322.
   PubMed Web of Science ®Google Scholar
• SANOVICH E, BARTUS RT, FRIDEN PM, DEAN RL, LE HQ, BRIGHTMAN M: Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Broth Res. (1995) 705:125–135.
   PubMed Web of Science ®Google Scholar
• CHI OZ, CHANG Q, WANG G, WEISS HR: Effects of nitric oxide on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Arresth. Arralg. (1997) 84:370–375.
   PubMed Web of Science ®Google Scholar
• KESSLER RM, GOBLE JC, BIRD JH etal.: Measurement of blood-brain barrier permeability with positron emission tomography and [68GalEDTA. I Cereb. Blood Flow Metab. (1984) 4:323–328.
   Google Scholar
• ZUNKELER B, CARSON RE, OLSON J etal.: Hyperosmolar blood-brain barrier disruption in baboons: an in vivo study using positron emission tomography and rubidium-82. I Neurosurg. (1996) 84:494–502.
   Google Scholar
• ZUNKELER B, CARSON RE, OLSON J etal.: Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J. Neurosurg. (1996) 85:1056–1065.
   Google Scholar
• •Confirms efficacy of osmotic barrier opening in human subjects.
   Google Scholar
• ARMSTRONG BK, ROBINSON PJ, RAPOPORT SI: Size-dependent blood-brain barrier opening demonstrated with [14C1sucrose and a 200,000-Da [31-11dextran. Exp. Neural. (1987) 97:686–696.
   PubMedGoogle Scholar
• ARMSTRONG BK, SMITH QR, RAPOPORT SI, STROHALM J, KOPECEK J, DUNCAN R: Osmotic opening of the blood-brain barrier permeability to n-(2-hydroxypropyl) methacrylamide copolymers. Effect of polymer Mw, charge and hydrophobicity. Controlled Release (1989) 10:27–35.
   Web of Science ®Google Scholar
• FENSTERMACHER JD, JOHNSON JA:Filtration and reflection coefficients of the rabbit blood-brain barrier. Am. I Physiol. (1966) 211:341–346.
   PubMed Web of Science ®Google Scholar
• MULDOON LL, NILAVER G, KROLL RA et al.: Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpes virus, and iron oxide particles to normal rat brain. Am. J. Athol (1995) 147:1840–1851.
   PubMed Web of Science ®Google Scholar
• CHI OZ, LU X, WEI HM, WILLIAMS JA, WEISS HR: Hydroxyethyl starch solution attenuates blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Arresth. Arralg. (1996) 83:336–341.
   PubMed Web of Science ®Google Scholar
• HICKS JT, ALBRECHT P, RAPOPORT SI: Entry of neutralizing antibody to measles into brain and cerebrospinal fluid of immunized monkeys after osmotic opening of the blood brain barrier. Exp. Neural. (1976) 53:768–779.
   PubMed Web of Science ®Google Scholar
• NEU WELT EA, BARNETT PA, HELLSTROM I et al: Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res. (1988) 48:4725–4729.
   PubMed Web of Science ®Google Scholar
• REMSEN LG, TRAIL PA, HELLSTROM I, HELLSTROM KE, NEUWELT EA: Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery (2000) 46:704–709.
   PubMed Web of Science ®Google Scholar
• CHIUEH CC, SUN CL, KOPIN IJ, FREDERICKS WR, RAPOPORT SI: Entry of l3H1norepinephrine, [125Il albumin and Evans blue from blood into brain following unilateral osmotic opening of the blood-brain barrier. Brain Res. (1978) 145:292–301.
   Google Scholar
• BARRANGER JA, RAPOPORT SI, FREDERICKS WR et al: Modification of the blood-brain barrier: increased concentration and fate of enzymes entering the brain. Proc. Natl. Acad. Sci. USA (1979) 76:481–485.
   PubMed Web of Science ®Google Scholar
• OHATA M, FREDERICKS WR, NEU WELT EA, SUNDARAM U, RAPOPORT SI: l3H1Methotrexate loss from the rat brain following enhanced uptake by osmotic opening of the blood-brain barrier. Cancer Res. (1985) 45:1092–1096.
   PubMed Web of Science ®Google Scholar
• •Study indicating clearance as well as barrier opening critical for determining drug effect in brain.
   Google Scholar
• ZYLBER-KATZ E, GOMORI JM, SCHWARTZ A, LOSSOS A, BOKSTEIN F, SIEGAL T: Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Chia. Pharmacol Ther. (2000) 67:631–641.
   PubMed Web of Science ®Google Scholar
• LEVINE RL, FREDERICKS WR, RAPOPORT SI: Clearance of bilirubin from rat brain after reversible osmotic opening of the blood-brain barrier. Pediam Res. (1985) 19:1040–1043.
   PubMed Web of Science ®Google Scholar
• GREIG NH, FREDERICKS WR, HOLLOWAY HW, SONCRANT TT, RAPOPORT SI: Delivery of interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat. Pharmacy]. Exp. Ther. (1988) 245:581–586.
   Google Scholar
• TAKAHASHI M, TSUTSUI H, MURAYAMA C, MIYAZAWA T, FRITZ-ZIEROTH B: Neurotoxicity of gadolinium contrast agents for magnetic resonance imaging in rats with osmotically disrupted blood-brain barrier. Magri. Reson. Imaging (1996) 14:619–623.
   PubMed Web of Science ®Google Scholar
• NEU WELT EA, DAHLBORG SA, GOLDMAN D, DANA B, RAMSEY FL: Significant prolongation of survival of primary CNS lymphoma patients by combination chemotherapy given in association with osmotic blood-brain barrier disruption. Proc. Am. Ass. Cancer Res. (1989) 30:264.
   Google Scholar
• YANG W, BARTH RF, CARPENTER D, MOESCHBERGER ML, GOODMAN JH: Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery (1996) 38:965–992.
   Google Scholar
• RAO S, MILLER PJ, LAPCHAK PA: Enhanced delivery of [125I1g1ia1 cell line-derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification. Neurosci. Lett. (1996) 220:187–190.
   PubMed Web of Science ®Google Scholar
• TOMIWA K, HAZAMA F, MIKAWA H: Neurotoxicity of vincristine after the osmotic opening of the blood-brain barrier. Neurapathal Appl. Neurobial. (1983) 9:345–354.
   PubMed Web of Science ®Google Scholar
• BHATTACHARJEE AK, NAGASHIMA T, KONDOH T, TAMAKI N: The effects of the Na+/Ca++ exchange blocker on osmotic blood-brain barrier disruption. Brain Res. (2001) 900:157–162.
   PubMed Web of Science ®Google Scholar
• ••Na±/Ca2+ channel blocker markedlyprolongs osmotically-initiated blood-brain barrier opening in vivo.
   Google Scholar
• TATOR CH: Chemotherapy of brain tumors: uptake of tritiated methotrexate by a transplantable intracerebral ependymoblastoma in mice. j Neurosurg. (1972) 37:1–8.
   PubMed Web of Science ®Google Scholar
• •Drugs need access to the growing edge of intracerebral tumors, where the blood-brain barrier may be intact.
   Google Scholar
• WARNKE PC, BLASBERG RG, GROOTHUIS DR: The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann. Neural (1987) 22:300–305.
   PubMed Web of Science ®Google Scholar
• HIESIGER EM, VOORHIES RM, BASLER GA, LIPSCUHTZ LE, POSNER JB, SHAPIRO WR: Opening the blood-brain and blood-tumor barriers in experimental rat brain tumor: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann. Neural (1986) 19:50–59.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI: Osmotic opening of theblood-brain barrier. Ann. Neural. (1988) 24:677–680.
   PubMed Web of Science ®Google Scholar
• RAPOPORT SI, ROBINSON PJ: A therapeutic role for osmotic opening of the blood-brain barrier. Re-evaluation of literature and of importance of source-sink relations between brain and tumor. In: Pathophysiology of the Blood-Brain Barrier Long Term Consequences of Barrier Dysfunction for the Brain. BB Johanson, C Owman, H Widner (Eds.) Fernstrom Foundation Series., Amsterdam, Elsevier, The Netherlands (1990)14:167–181.
   Google Scholar
• WALKER M: Treatment of brain tumors.Med. Cilia. North. Am. (1977) 61:1045–1051.
   PubMed Web of Science ®Google Scholar
• ROBINSON PJ, RAPOPORT SI: Model for drug uptake by brain tumors: Effects of osmotic treatment and of diffusion in brain. Cereb. Blood Flow Metab. (1990) 10:153–161.
   PubMed Web of Science ®Google Scholar
• SATO S, KAWASE T, HARADA S, TAKAYAMA H, SUGA S: Effect of hyperosmotic solution on human brain tumor vasculature. Acta Neurochir (Wien) (1998) 140:1135–1141.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN MC, MUROVIC JS, LEVIN VA: Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology (1988) 38:1371–1374.
   PubMed Web of Science ®Google Scholar
• DEANGELIS LM: Cerebral lymphoma presenting as a nonenhancing lesion on a computed tomographichnagnetic resonance scan. Ann. Neural. (1993) 33:308–311.
   PubMed Web of Science ®Google Scholar
• DOOLITTLE ND, PETRILLO A, BELLS, CUMMINGS P, ERIKSEN S: Blood-brain barrier disruption for the treatment of malignant brain tumors: The National Program. j Neurosci. Nurs. (1998) 30:81–90.
   PubMedGoogle Scholar
• DOOLITTLE ND, MINER ME, HALL WA etal.: Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer (2000) 88:637–647.
   Google Scholar
• ••Latest data from clinical trials withosmotic barrier opening in patients with malignant brain tumors.
   Google Scholar
• SHAPIRO WR, GREEN SB, BURGER PC et al: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. j Neurosurg. (1992) 76:772–781.
   PubMed Web of Science ®Google Scholar
• WATNE K, HANNISDAL E, NOME 0, HAGER B, HIRSCHBERG H: Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. Net/cos/age/y(1992) 30:223–227.
   Google Scholar
• OKISAKA S, KUWABARA T, RAPOPORT SI: Selective destruction of the pigmented epithelium in the ciliary body of the eye. Science (1974) 184:1298–1299.
   PubMed Web of Science ®Google Scholar
• MILLAY RH, KLEIN ML, SHULTS WT, DAHLBORG SA, NEU WELT EA: Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. Am. j Ophthalmol. (1986) 102:626–632.
   PubMed Web of Science ®Google Scholar
• DOOLITTLE ND, MULDOON LL, BRUMETT RE et al.: Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Cilia. Cancer Res. (2001) 7:493–500.
   PubMed Web of Science ®Google Scholar
• GUMERLOCK MK, YORK D, DURKIS D: Visual evoked responses as a monitor of intracranial pressure during hyperosmolar blood-brain barrier disruption. Acta Neurochir (1994) 60(Suppl.):132–135.
   Google Scholar
• RAPOPORT SI: Effect of concentrated solutions on blood-brain barrier. Am. Physial. (1970) 219:270–274.
   PubMed Web of Science ®Google Scholar
• •First study in which theory of osmotic barrier opening in proposed.
   Google Scholar
• SMITH QR: Drug delivery to brain and the role of carrier-mediated transport. Adv. Exp. Med. Biol. (1993) 331:83–93.
   PubMedGoogle Scholar
• GJEDDE A, REITH J, LÉGER G et al: Blood-brain barrier removal of DOPA: Role in regulation of dopamine synthesis and treatment of Parkinson's disease. In: New Concepts of a Blood-Brain Barrier Greenwood J, Begley D, Segal M (Eds.) London, Plenum, UK (1995):103–109.
   Google Scholar
• FISHMAN JB, RUBIN J, HANDRAHAN JV, CONNOR JR, FINE RE: Receptor-mediated transcytosis of transferrin across the blood-brain barrier. j Neurosci. Res. (1987) 18:299–304.
   PubMed Web of Science ®Google Scholar
• FRIDEN PM, WALUS LR, WATSON P et al.: Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science (1993) 259:373–377.
   PubMed Web of Science ®Google Scholar
• DEHOUCK B, FENART L, DEHOUCK MP PIERCE A, TORPIER G, CECCHELLI R: A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. j Cell Biol. (1997) 138:877–889.
   PubMed Web of Science ®Google Scholar
• INAMURA T, NOMURA T, BARTUS RT, BLACK KL: Intracarotid infusion of RIV1P- 7, a bradykinin analog: a method for selective drug delivery to brain tumors. Neurosurg. (1994) 81(5):752–758.
   Web of Science ®Google Scholar
• BARTUS RT, SNOD GRASS E MARSH J, AGOSTINO M, PERKINS A, EMERICH DF: Intravenous cereport (RIV1P-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platelet levels, and enhances survival. ..J. Pharmacol. Exp. Ther. (2000) 293:903–911.
   PubMed Web of Science ®Google Scholar
• WESTERGREN I, JOHANSSON BB: Altering the blood-brain barrier in the rat by intracarotid infusion of polycations: a comparison between protamine, poly-L-lysine and poly-L-arginine. Acta Physiol. Scalar/. (1993) 149:99–104.
   PubMedGoogle Scholar
• CHABNER BA, YOUNG RC: Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. j Cirri. Invest. (1973) 52:1804–1811.
   PubMed Web of Science ®Google Scholar
• HOSHINO T, WILSON CB, ROSENBLUM ML, BARKER M: Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. Neurosurg. (1975) 43:127–135.
   Web of Science ®Google Scholar
• KRAEMER DF, FORTIN D, DOOLITTLE ND, NEUWELT EA: Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery (2001) 48:1040–1041.
   Google Scholar
• PRICE DL, WONG PC, MARKOWSKA AL et al.: The value of transgenic models for the study of neurodegenerative disease. Ann. NY Acad. Sci. (2000) 920:179–191.
   PubMed Web of Science ®Google Scholar
• KIMURA S, GONZALEZ FJ: Applicationsof genetically manipulated mice in pharmacogenetics and pharmacogenomics. Pharmacology (2000) 61:147–153.
   PubMed Web of Science ®Google Scholar
• FREDERICKS WR, RAPOPORT SI: Reversible osmotic opening of the blood-brain barrier in mice. Stroke (1988) 19:266–268.
   PubMed Web of Science ®Google Scholar
• MADAJEWICZ S, CHOWMAN N, TFAYLI A, ROQUE C, MEEK A, DAVIS R etal.: Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer (2000) 88:2350–2356.
   Google Scholar